0001062993-24-006058.txt : 20240308
0001062993-24-006058.hdr.sgml : 20240308
20240308182955
ACCESSION NUMBER: 0001062993-24-006058
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240306
FILED AS OF DATE: 20240308
DATE AS OF CHANGE: 20240308
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Farid Adrienne
CENTRAL INDEX KEY: 0001867310
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40498
FILM NUMBER: 24736063
MAIL ADDRESS:
STREET 1: C/O CENTURY THERAPEUTICS, INC.
STREET 2: 3675 MARKET STREET
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Century Therapeutics, Inc.
CENTRAL INDEX KEY: 0001850119
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 842040295
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 25 N 38TH STREET, 11TH FLOOR
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
BUSINESS PHONE: 215-981-4000
MAIL ADDRESS:
STREET 1: 25 N 38TH STREET, 11TH FLOOR
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0508
4
2024-03-06
0001850119
Century Therapeutics, Inc.
IPSC
0001867310
Farid Adrienne
C/O CENTURY THERAPEUTICS, INC.
25 N 38TH STREET, 11TH FLOOR
PHILADELPHIA
PA
19104
0
1
0
0
Chief Operations Officer
0
Common Stock
2024-03-06
4
M
0
30684
1.03
A
144833
D
Common Stock
2024-03-06
4
S
0
30684
4.9648
D
114149
D
Common Stock
2024-03-07
4
M
0
22831
1.03
A
136980
D
Common Stock
2024-03-07
4
S
0
22831
5.1396
D
114149
D
Stock Option (right to buy)
1.03
2024-03-06
4
M
0
30684
0
D
2029-07-17
Common Stock
30684
191486
D
Stock Option (right to buy)
1.03
2024-03-07
4
M
0
22831
0
D
2029-07-17
Common Stock
22831
168655
D
The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.85 to $5.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.87 to $5.48, inclusive.
The option is fully vested and exercisable.
/s/ Adrienne Farid
2024-03-08